Clinical Trial

Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Corneal stromal injection is an emerging local drug delivery method, characterized by strong targeting, high drug concentration, and prolonged duration of action. It has been preliminarily applied in the treatment of fungal keratitis and neurotrophic corneal diseases. This study aims to investigate the safety and efficacy of anti-VEGF drugs delivered via corneal stromal injection in neovascularization caused by HSK (Herpes Simplex Keratitis). The study has clear medical significance and technical feasibility, and it is expected to promote innovation in the treatment paradigm for corneal neovascularization.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07329686
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Herpes Simplex Keratitis, Corneal Neovascularization
Enrollment 100 participants
Start Date 2025-10-01
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-01-09